PerformRx

Formed in 1999, PerformRx, LLC is a URAC accredited pharmacy benefits manager servicing lines of business including Medicaid, Medicare, and Commercial markets. A large percentage of the staff at PerformRx are pharmacists and pharmacy technicians. This ensures that the company maintains a culture of clinical influence and care throughout each business area. Clients receive a personalized solution designed to understand their benefit and meet their needs. This includes offering clients standalone products and services as well as full pharmacy benefit management. PerformRx ensures these solutions by utilizing technology that adapts to specific member populations and changes in the health care landscape.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

The 2nd Saudi International Pharma Expo

Drug Delivery and Nanomedicine

3rd European Conference on Pharmacovigilance and Drug Safety

Pharmaceutics And Novel Drug Delivery Systems

Global Pharma And Drug Delivery Summit

24th World Congress On Pharmaceutical Research and Drug Discovery

Related News

MOLECULIN ANNOUNCES NEW ANTIVIRAL DRUG CANDIDATES DEMONSTRATE IN VITRO ACTIVITY AGAINST HIV

Moleculin Biotech, Inc | October 07, 2020

Moleculin Biotech, Inc., (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing significant in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV...

BUSINESS INSIGHTS

JAZZ PHARMACEUTICALS ANNOUNCES AGREEMENT TO DIVEST SUNOSI® (SOLRIAMFETOL) TO AXSOME THERAPEUTICS

Jazz Pharmaceuticals plc | March 28, 2022

Jazz Pharmaceuticals plc announced that it has entered into a definitive agreement to divest Sunosi® a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea to Axsome Therapeutics. Under the terms of the agreement, Axsome will receive the rights to Sunosi in all of the existing territories available to Jazz. Jazz will receive attractive financial terms including a...

PHARMA TECH

QUANTUM LEAP AND SIGNALPATH TO INTEGRATE CLINICAL TRIAL SOFTWARE INFRASTRUCTURE ACROSS I-SPY PLATFORM TRIALS

Quantum Leap, SignalPath | February 24, 2021

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath reported a partnership today that will further enable the I-SPY platform trials with vigorous, streamlined technology infrastructure to drive the straightforwardness and efficiency of trial execution. SignalPath will integrate existing work process instruments being utilized to control the I-SPY trials into SignalPath's research operations and financial platform. In view of the public health emergency surrounding the COVID-19 ...

PHARMA TECH

FORESEE PHARMACEUTICALS AND TRPHARM ANNOUNCE LICENSE AND CO-DEVELOPMENT AGREEMENT

Foresee Pharmaceuticals Co., Ltd | February 24, 2022

Foresee Pharmaceuticals Co., Ltd. a Taiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and commercialisation in Turkey and certain MENA countries of Foresee's FP-045 program, an oral allosteric Aldehyde Dehydrogenase 2 (ALDH2) activator for the treatment of Fanconi Anemia and other rare and severe diseases. Under the terms of this partnership, Forese...